Why DBV Technologies S.A.’s (DBVT) Stock Is Down 5.59%
As of Thursday, September 24, DBV Technologies S.A.’s DBVT share price has dipped by 5.59%, which has investors questioning if this is right time to buy.Michael Rose
A+ Stock Grade Summary:
| VALUE: |
|
|
| GROWTH: |
|
|
| MOMENTUM: |
|
|
| EPS REVISIONS: |
|
|
| QUALITY: |
|
|
COMPANY SUMMARY
DBV Technologies S.A., a clinical-stage biopharmaceutical company, engages in the research and development of epicutaneous immunotherapy products in France. Its product pipeline comprising Viaskin Peanut, an immunotherapy product, which has completed Phase 3 clinical trial for the treatment of peanut allergies; and Viaskin Milk which is in Phase 1/2 clinical trial for the treatment of immunoglobulin E (IgE) mediated or cow’s milk protein allergy and eosinophilic esophagitis. The company’s earlier stage research programs include celiac disease. In addition, the company develops Viaskin technology platform, a platform to potentially treat food allergy. It has a collaboration with Nestlé Health Science to develop MAG1C, a ready-to-use atopy patch test for the diagnosis of non-IgE mediated CMPA in infants and toddlers. DBV Technologies S.A. was incorporated in 2002 and is headquartered in Châtillon, France.
Commentary & Analysis
Why DBV Technologies S.A.’s (DBVT) Stock Is Up 6.45%
As of Thursday, September 17, DBV Technologies S.A.’s DBVT share price has surged by 6.45%, which has investors questioning if this is right time to sell.Rosalio Madrigal
Why DBV Technologies S.A.’s (DBVT) Stock Is Down 7.44%
As of Friday, September 11, DBV Technologies S.A.’s DBVT share price has dipped by 7.44%, which has investors questioning if this is right time to buy.Cynthia McLaughlin
Why DBV Technologies S.A.’s (DBVT) Stock Is Up 5.52%
As of Tuesday, August 25, DBV Technologies S.A.’s DBVT share price has surged by 5.52%, which has investors questioning if this is right time to sell.Michael Rose
Why DBV Technologies S.A.’s (DBVT) Stock Is Up 5.35%
As of Monday, August 17, DBV Technologies S.A.’s DBVT share price has surged by 5.35%, which has investors questioning if this is right time to sell.Michael Rose
Financial Summary
| Share Statistics | DBVT | Industry Median |
Percentile (All Stocks) |
|
| Market Cap (Mil) | $680.6 | $257.9 | 41% |
|
| Shares Out (Mil) | 433.5 | 54.3 | 87% |
|
| Institutional Ownership | 99.9% | 92.9% | 96% |
|
| Float (Mil) | 174.7 | 41.4 | 71% |
|
| Beta | -0.21 | 0.95 | 3% |
|
| Avg Daily Volume (000s) | 231 | 674 | 44% |
|
| Price Change (52-week) |
23.5% | 51.5% | 70% |
|
| Growth | DBVT | Industry Median |
Percentile (All Stocks) |
|
| Sales (5yr) | (13.1%) | 13.2% | 4% |
|
| Net Income (5yr) | 1.6% | (10.1%) | 42% |
|
| EPS (5yr) | 18.6% | 15.8% | 66 |
|
| Dividends (5yr) | 0.0% | 0.0% | 0% |
|
| Cash Flow (5yr) | 80.8% | (15.6%) | 97% |
|
| Estimates | Qtrly | Current Fiscal Year |
Next Fiscal Year |
|
| # of Estimates | 3 | 5 | 4 | |
| Current EPS | ($0.166) | ($0.519) | ($0.491) | |
| Month Ago EPS | ($0.166) | ($0.390) | ($0.166) | |
| # Rev Up | 1 | 0 | 0 | |
| # Rev Down | 0 | 1 | 1 | |
| Three Months Ago EPS | ($0.139) | ($0.384) | ($0.164) | |
| Year/Year Chg | 43.1% | (50.7%) | (90.3%) | |
| Financials | DBVT | Industry Median |
Percentile (All Stocks) |
|
| Sales (TTM) (Mil) | $5 | $37 | 6% |
|
| Net Income (TTM) (Mil) | ($176) | ($43) | 7% |
|
| EPS (TTM) | ($0.601) | ($1.600) | 26% |
|
| Operating Cash Flow (TTM) (Mil) | ($169) | ($32) | 4% |
|
| Net Cash Flow (TTM) (Mil) | $72 | $2 | 74% |
|
| Long-Term Debt (Q1) (Mil) | $7 | $4 | 26% |
|
| Enterprise Value (Q1) (Mil) | $632 | $174 | 36% |
|
| Valuation | DBVT | Industry Median |
Percentile (All Stocks) |
|
| P/B | 21.41 | 2.51 | 96% |
|
| P/E | na | 19.4 | na |
|
| Dividend Yield | 0.0% | 0.0% | 0% |
|
| PEG (5yr hist) | na | 1.0 | na |
|
| Ratios | DBVT | Industry Median |
Percentile (All Stocks) |
|
| Gross Margin | 100.0% | 68.9% | 96% |
|
| Net Margin | na | (72.5%) | na |
|
| ROA | (96.0%) | (47.7%) | 6% |
|
| ROE | (142.7%) | (54.9%) | 6% |
|
| Liabilities to Assets | 28.1% | 29.1% | 20% |
|
| F-Score | 3 | 3 | 18% |
|
Passing Stock Screens
As of 9/25/2026, from a list of 60 stock screening strategies,
FACTOR STRATEGY
Est Rev: Lowest 30 Down
Factors: Earnings Estimates
Introduction to the use of earnings estimates.
| Performance Since Inception: | 3.3% |
| +/- S&P 500: | -4.2 |
FACTOR STRATEGY
Est Rev: Down 5% Screen
Factors: Earnings Estimates
Introduction to the use of earnings estimates.
| Performance Since Inception: | 2.8% |
| +/- S&P 500: | -4.7 |
